Meet the Experts Transporter Conference Boston 2015
Welcome
As a pioneer in the drug transporter field for the past 15 years, SOLVO is dedicated to exploring the science of transporters and their role in drug efficacy and safety. With frequent webinars, numerous peer-reviewed publications, and our Transporter Book, we are to continually striving to expand our scientific contribution to the transporter field. Our Meet the Experts conference series provides a unique atmosphere and informal environment, delivering an excellent opportunity for in-depth scientific discussions featuring prominent scientists and thought leaders. Our goals are to catalyze scientific interactions and collaborations based upon research at the forefront of transporter science.
Previous events in the Meet the Experts: Transporter Conference series have been held in Budapest, San Francisco and Tokyo, with over 250 attendees from both industry and academia. Details of these past events can be checked on the conference section of the website.
After the great success of previous events SOLVO is pleased to announce the next conference to be held October 5-6, 2015 in Boston, MA .
Building upon suggestions from previous events, the sessions will focus on industry applications and features several key opinion leaders in the field of transporter science.
Venue Information
Conference will be organized at Boston Marriott Newton Hotel: 2345 Commonwealth Avenue Newton Massachusetts 02466 USA.Conference sponsors:
2.jpg){kind=logo}
Agenda
Here you can download the Conference Agenda!
|
Program |
|
|
Title |
Speaker |
|
Day 1 |
|
|
Introduction |
Péter KRAJCSI, SOLVO Biotechnology |
|
Methods and models to study barriers |
|
|
Evaluation and Application of In Vitro and Preclinical Animal Models to Study OATP-Mediated Drug Disposition |
Xiaoyan CHU, Merck |
|
Interplay between Passive Permeability and Active Transport on CNS Drug Exposure and Activity |
J. Cory KALVASS, Abbvie |
|
Judit PONGRACZ, Humeltis |
|
|
Dan BOW, AbbVie |
|
|
Sponsored presentation |
|
|
Advanced In Vitro Tools for Addressing Complex Transporter Issues |
Maureen BOURNER, Sigma-Aldrich |
|
Day 2 |
|
|
Transporter - enzyme interplays |
|
|
Transporter - OATs and Other Transporters in Metabolism: The Remote Sensing and Signaling Hypothesis |
Kevin BUSH, University of California |
|
Microengineered Liver Models for Applications in Drug Development |
Salman KHETANI, University of Illinois |
|
Drug Metabolites and Transporters: Perspectives and Issues for Drug Development |
Maciej ZAMEK-GLISZCZYNSKI, GSK |
|
Genotype or Phenotype: Precision Medicine and the Sources of Variable Drug Transport and Exposure |
Nathan CHERRINGTON, University of Arizona |
|
Transporters - role in drug response, toxicity |
|
|
Michael GOTTESMAN, National Institute of Health |
|
|
Uptake Transporters as Mediators of Drug Efficacy and Toxicity |
Michael SAWYER, Alberta Health Services |
|
Androgens in Prostate Cancer: Active or Passive Entry |
W. Douglas FIGG, National Institute of Health |
|
Basolateral Efflux: Importance in Predicting Biliary Clearance and Hepatotoxicity |
Kenneth BROUWER, Qualyst |
|
Closing remarks |
|
Speakers
The following speakers are presenting at the conference:
BOURNER Maureen, Ph.D.
Principal Scientist ADME/Tox Sigma-Aldrich St. Louis, MO, USA
Biography
Maureen Bourner is a Principle Scientist in the ADME/Tox group at Sigma-Aldrich, St. Louis, MO. She has worked in the pharmaceutical industry for Monsanto Co./G.D. Searle/Pharmacia Corp./Pfizer, Inc. for the past 20 years. Her responsibilities included project leadership responsibilities in allergy and respiratory where she lead a team of scientists that designed and implemented a testing funnel to triage compounds for the establishment of structure activity relationships for inflammation readouts. In oncology, her team identified new targets through transcriptional profiling and established siRNA transfections conditions in a variety of mammalian cell lines to determine the role of specific genes and pathways in disease modification. As project leader in COPD designed mechanism of action studies to establish confidence in rationale for new targets in COPD with existing compounds known to inhibit the target and developed cell efficacy assays and screening of compounds to identify anti-inflammatory and anti-mucolytic agents for the treatment of COPD. Since joining Sigma-Aldrich in 2010, her primary responsibilities have been to lead a team of scientists to develop novel cell lines and cell based assays using genomic modification techniques in the field of ADME toxicology. Using zinc finger nuclease technology her team has created transporter knock-out cell lines in enterocytes (C2bbe1 cells), liver (HepaRG cells) and kidney (REPTC). She has been a key leader in the establishment of a services group providing transporter assays using these novel cell lines as well as developing methods to provide these cell lines in assay ready format for customers to use in their own laboratories. These novel cell lines have proven to be a valuable tool for clarifying complex drug-transporter interactions which were previously misclassified when traditional chemical or genetic knock down approaches were employed and provide a unique platform for assessing interactions when more than one transporter is involved.
BOW Daniel, Ph.D.
Group Leader, DMPK Global Pharmaceutical R&D AbbVie Inc. North Chicago, IL, USA
Biography
Dan Bow leads the drug transporter group at AbbVie, where he is responsible for drug transporter activities and provides pre-clinical DMPK support for multiple discovery and development projects. He received his PhD from the University of Aberdeen, Scotland where his research focused on renal organic anion and cation transport. In 2002, he moved to the United States and continued research in the area of renal transport with a visiting fellow position at the National Institute of Environmental Health Sciences in North Carolina. Prior to joining AbbVie in 2007, he held a post doctoral position at the University of North Carolina at Chapel Hill, where his research interests were on drug transporter localization in hepatocytes, transporter expression, and canalicular membrane development in the hepatocyte sandwich-culture model. Current research interests include the interpretation of endogenous substrate exposure related to metabolism and transport, drug and drug transporter trafficking, and the translation of pre-clinical transporter data to the clinic. In 2013, he was a co-author on an International Transporter Consortium (ITC) white paper; “In Vitro Methods to Support Transporter Evaluation in Drug Discovery and Development” and in 2014 was invited to join the ITC as a main committee member. Dan chaired the AAPS Drug Transporter Focus Group from 2012-2014, and was recently elected to serve as AAPS section vice chair for PPDM (2015). He has been involved in organization of the bi-annual AAPS Drug Transporter workshop since 2011 and partnered with the ITC to co-chair the 2015 AAPS/ITC Joint Workshop on Drug Transporters.
BROUWER R. Kenneth, PhD., RPh.
Chief Scientific Officer Qualyst Transporter Solutions, LLC Durham, NC,USA
Biography
Dr. Brouwer is Chief Scientific Officer at Qualyst Transporter Solutions, a company focused on providing solutions to transporter questions that arise during drug discovery and development in the areas of hepatic drug transport (B-CLEAR®), drug interactions, and evaluation of hepatotoxicity. Prior to this, Dr. Brouwer served as Executive Director, Drug Metabolism and Pharmacokinetics, at PPD Discovery, USA, where he had responsibility for overseeing the scientific and administrative operations within the preclinical groups at PPD Discovery, including the areas of metabolism, pharmacokinetics, toxicology; absorption technologies, and Pharmazyme groups. Before joining PPD Discovery, he served as Director, Preclinical Development, Drug Metabolism and Pharmacokinetics at GlaxoSmithKline. In addition, he was responsible for the drug metabolism and pharmacokinetics developability strategy leading to candidate selection, review of drug candidate project plans prior to candidate selection, and developing and implementing process to ensure a smooth transition from candidate selection to full development. Over his 18 year tenure at GlaxoSmithKline, Dr Brouwer held positions of increasing responsibility in both Clinical Pharmacokinetics and Drug Metabolism. Dr. Brouwer has successfully lead and directed large international multidisciplinary project teams to support the product development of 4 high priority development candidates. He has been the Drug Metabolism Project Team Leader for 12 Development compounds and 6 Discovery compounds. He has served as the Pharmacokinetics and Drug Metabolism expert at FDA panel presentations for GlaxoSmithKline, and has authored or co-authored over 400 company reports to support ERC, CTX, IND, NDA and MAA regulatory submissions. Dr. Brouwer has over 60 publications in peer reviewed journals, and is the holder of 3 patents. Dr. Brouwer serves on the Editorial Advisory Board for the Journal of Pharmaceutical Sciences, and is a reviewer for several additional journals. Dr. Brouwer is an adjunct faculty member in the Division of Molecular Pharmaceutics at the School of Pharmacy, University of North Carolina.
CHERRINGTON Nathan, Ph.D
Head of the Department of Pharmaceutical Sciences and Director of Graduate Studies College of Pharmacy at the University of Arizona Tucson, AZ, USA
Biography
NATHAN J. CHERRINGTON, Ph.D. is a Professor and 1885 Society Distinguished Scholar in the Department of Pharmacology and Toxicology. He is the head of the Department of Pharmaceutical Sciences and Director of Graduate Studies in the College of Pharmacy at the University of Arizona. He received a B.S. in Zoology from Brigham Young University and a Ph.D. in Toxicology from North Carolina State University with an emphasis on xenobiotic metabolism. He then moved to the University of Kansas Medical Center to pursue postdoctoral training in drug metabolism and disposition. He has taught Drug Metabolism and Disposition, Systems Toxicology, Environmental Health Science, and Advanced Toxicology courses since joining the faculty at the University of Arizona in 2002. Nathan has published over 90 original research papers on the sources of inter-individual variability in pharmacogenomics. He serves as an associate editor for Toxicological Sciences, and on the editorial board of Drug Metabolism and Disposition, and Journal of Molecular and Biochemical Toxicology. He has served on numerous NIH study sections where he is a current member of the NIEHS Environmental Health Sciences Review Committee, as well as several committees for the Society of Toxicology and the International Society for the Study of Xenobiotics. He was recently awarded the Achievement Award by the Society of Toxicology, the Alumni Achievement Award from Brigham Young University, and was made a fellow of the Academy of Toxicological Sciences. His current research is on the effect of underlying disease states on an individual’s ability to metabolize and eliminate drugs.
CHU Xiaoyan, Ph.D.
Senior Principle Scientist Merck &Co. Rahway, NJ, USA
Biography
Dr. Xiaoyan Chu is a Senior Principle Scientist in the Department of Pharmacokinetics, Pharmacodynamics & Drug Metabolism (PPDM), Merck & Co., Inc., Rahway, NJ. She received her Ph.D. from the Department of Molecular Pharmacokinetics, Graduate School of Pharmaceutical Sciences, University of Tokyo, Japan. After completing her post-doctoral research at the Department of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, she joined the Department of PPDM at Merck & Co., Inc. As the scientific leader for the Transporter & In Vitro Technology Group, her main responsibilities are to develop transporter strategies to support Merck discovery and development portfolio, and to evaluate and establish new technologies to study the role of drug transporters in drug disposition and drug-drug interactions. She has authored 70 peer-reviewed research papers, book chapters, and is an invited speaker at over 30 national/international scientific conferences. She is a member of the International Transport Consortium (ITC) and serves as organizer and steering committee member of various scientific meetings/organizations.
FIGG William Douglas, Ph.D
Senior Investigator, Head of the Clinical Pharmacology Program and Head of Molecular Pharmacology Section and Deputy Branch Chief in the Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
Biography
Dr. William Douglas Figg received his BS in Biology from Georgetown College, his BS in Pharmacy from Samford University and his doctoral degree from Auburn University. He completed his internship at the University of Alabama at Birmingham Hospital and his fellowship in Drug Development at the University of North Carolina, Chapel Hill. He also received an MBA degree from a combined program at Columbia University and the London Business School. Dr. Figg joined the National Cancer Institute in 1992. The following year he became head of the Molecular Pharmacology Section and the Clinical Pharmacology Program. Since then his research has focused on using pharmacological principles to optimize the treatment of cancer and on identifying genes involved in the development of prostate cancer. He has been the PI of over 25 clinical trials for men with metastatic prostate cancer. Dr. Figg has over 625 peer-reviewed publications. He has received numerous awards and honors, including the Leon Goldberg Award from ASCPT, the Allen J Brands Award from US Public Health Service, the Russell R. Miller Award from ACCP, the Andrew Craigie Award from AMSUS and the Sustained Contribution to the Scientific Literature award from ASHP. Dr. Figg is adjunct faculty at Columbia University’s College of Physicians and Surgeons and serves as adjunct at several schools of pharmacy throughout the country.
GOTTESMAN Michael, M.D.
Chief, Laboratory of Cell Biology Center for Cancer Research, NCI, NIH Deputy Director for Intramural Research, NIH Bethesda, MD, USA
Biography
Dr. Gottesman has been Deputy Director for Intramural Research at NIH since 1993. A graduate of Harvard College summa cum laude and Harvard Medical School magna cum laude, Dr. Gottesman completed an internship and residency in medicine at the Peter Bent Brigham Hospital in Boston. He was a research associate at NIH from 1971 to 1974. He returned to Harvard Medical School as an assistant professor before returning to NIH in 1976. Dr. Gottesman became Chief of the Laboratory of Cell Biology in the National Cancer Institute in 1990. From 1992 to 1993, he was Acting Director of the National Center for Human Genome Research, and he was Acting Scientific Director of the NCHGR in 1993. His research interests have ranged from how DNA is replicated in bacteria to how cancer cells elude chemotherapy. He has published extensively on these subjects, with over 500 scientific publications to his credit. He has helped to identify the human gene that causes cancer cells to resist many anticancer drugs. He has shown that this gene encodes a protein (P-glycoprotein, an ATP-binding cassette transporter) that pumps anticancer drugs out of drug-resistant human cancers and has used this information to create gene transfer vectors and to circumvent drug resistance in cancer. More recently his work has focused on the complexity of drug resistance in human cancers and the role of ABC transporters in contributing to this resistance. He has been a member of the Institute of Medicine (now the National Academy of Medicine) since 2003, the American Association of Physicians since 2007, and the American Academy of Arts and Sciences since 2009. For his work on multidrug resistance in cancer, he is a recipient of the Milken Family Medical Foundation Cancer Research Award, the Rosenthal Foundation Award, the American Society for Pharmacology and Experimental Therapeutics (ASPET) Award, and the Vallee Foundation Award in Biomedical Research. Dr. Gottesman has been actively involved in initiating several training and mentoring programs for high school students and teachers, as well as college, medical, and graduate students. As Deputy Director for Intramural Research at NIH, he has initiated an NIH-wide lecture series, and reformulated tenure and review processes in the intramural program. He has also instituted training programs for minority and disadvantaged students, loan repayment programs for clinical researchers at NIH, research training programs for medical students, and research integrity training activities for NIH fellows.
KALVASS J. Cory, Ph.D.
Senior Principal Research Scientist AbbVie Inc. North Chicago, IL, USA
Biography
J. Cory Kalvass, Ph.D., is a Senior Principal Research Scientist in Drug Metabolism and Pharmacokinetics at AbbVie. He received dual bachelor degrees in Biochemistry and Chemistry from the University of Rochester and his Ph.D. in Pharmaceutical Sciences from the School of Pharmacy at the University of North Carolina. He has 18 years experience as an ADME / PK/PD scientist in drug discovery, working at Pfizer, Eli Lilly and AbbVie. Dr. Kalvass’ research interests include the study of CNS drug penetration and action, including transporter kinetics, as well as applying PK/PD approaches for establishing in-vitro-to-in-vivo and preclinical-to-clinical correlations. He is a champion of “free drug hypothesis” and has refined equilibrium dialysis methods to better estimate free drug levels in in vitro incubations, plasma, brain as well as other tissues. He is the author of over 50 peer-reviewed publications and abstracts. Dr. Kalvass is recipient of a number of awards including 2009 AAPS Meritorious Manuscript Award.
KHETANI R. Salman, Ph.D
Associate Professor Department of Bioengineering University of Illinois Chicago, IL, USA
Biography
Dr. Khetani received his BS degrees, summa cum laude, in electrical engineering and biomedical engineering from Marquette University, and MS and PhD degrees in bioengineering from the University of California at San Diego (UCSD). He was a Jacobs fellow and National Science Foundation graduate fellow at UCSD. Dr. Khetani conducted his postdoctoral studies at MIT in the laboratory of Dr. Sangeeta Bhatia, professor in the Harvard-MIT Division of Health Sciences and Technology and a world-renowned leader in multi-scale liver tissue engineering and regenerative medicine. Dr. Khetani’s research has been published in peer-reviewed journals such as Drug Metabolism and Disposition, Toxicological Sciences, Nature Biotechnology and the Proceedings of the National Academy of Sciences. In 2007, Dr. Khetani co-founded Hepregen Corporation and led research there as director of research from 2008 to 2011 in order to bring to market bioengineered models of animal and human livers for pharmaceutical drug development. Dr. Khetani then started his academic faculty career in the department of mechanical engineering and school of biomedical engineering at Colorado State University (2011-2015) and recently transitioned as associate professor of bioengineering to University of Illinois at Chicago where he directs the Microfabricated Tissue Models laboratory. He is the recipient of the NSF CAREER award, and his research (past and current) has been funded by DOD, FDA, NIH, NSF, the State of Colorado, and major pharmaceutical companies.
KRAJCSI Péter, PhD
Chief Scientific Officer, SOLVO Biotechnology Budaors, Hungary
Biography
Dr. Peter Krajcsi has extensive experience in biotechnology. He received his PhD in biochemistry from University of Szeged and later a Doctor of Sciences degree in biological sciences from the Hungarian Academy of Sciences. In his academic career he has focused on three major topics (i) steroid receptors (ii) molecular biology of adenoviruses and (iii) apoptosis. For the past 13 years he has been working in R&D management positions for small and medium size enterprises in drug research and gene therapy in Hungary as well as in the United States. Since 2002 he is the Chief Scientific Officer of Solvo Biotechnology. At Solvo the focus is on membrane transporters and utilization of membrane transporter technology in drug discovery and development as well as in development of diagnostics tools for cancer and inflammatory diseases.
NIGAM Sanjay, M.D.
Nancy Kaehr Chair in Research, Professor of Pediatrics, Medicine (Nephrology) Cellular Molecular Medicine University of California San Diego, CS, USA
Biography
Sanjay K. Nigam is the Nancy Kaehr Chair in Research and Professor of Pediatrics, Medicine (Nephrology) and Cellular Molecular Medicine at Univ. of California San Diego. He received his MD from the University of Pennsylvania. He conducted his postdoctoral research at the Rockefeller Univ. with Nobel laureate Gunter Blobel. He did his clinical Nephrology fellowship training at Columbia. Prior to moving to UCSD, he was on the faculty of Harvard Medical School and served as Director of Renal Research at Brigham and Women's Hospital. His laboratory discovered the gene now known as OAT1 (originally NKT) as well as a number of other SLC22 transporters. His lab also first described the phenotypes of the OAT1, OAT3 and URAT1 knockout mice from a pharmacological, toxicological and physiological perspective. Extensive metabolomics analyses of these mice, as well as "omics" based metabolic reconstructions, led to the "Remote Sensing and Signaling Hypothesis" (Nature Rev. Drug Disc. 2015).
PONGRACZ Judit, Ph.D, DSc.
Chief Scientific Officer Humeltis Ltd. Pécs, Hungary
Biography
Prof Dr PONGRÁCZ, Judit Erzsébet received her BSc degree in Biochemistry, did her PhD in Immunology both at the University of Debrecen, Hungary, became drhabil in Medical Sciences at Pecs University, then in 2013 received the Academic Doctorate degree from the Hungarian Academy of Sciences. She spent 15 years in the United Kingdom working at the University of Birmingham first as a post-doc, then as a senior research scientist. Currently, she is a full professor at Pecs University, heads the Department of Pharmaceutical Biotechnology, director of the Biotechnology MSc Programme at the University of Pecs, and chief scientific officer of Humeltis Ltd, the University’s spin-off company based on Prof Pongracz’s granted patents in lung tissue engineering. Her research interests include: Molecular microenvironment of non-small cell lung cancers, side effects of cancer drugs, drug transporter activities within the lung, angiogenesis in pulmonary senescence and lung cancer, molecular background of COPD and the regulation of pulmonary aging mechanisms. She also works on modelling most pulmonary diseases in vitro. She’s holder of several national and international grants both in research and education. At Humeltis she is responsible for novel pulmonary tissue product development, toxicology and efficacy testing of drug candidates in pulmonary tissues and development of personalized applications for lung cancer treatment. She was honoured by the Women in Science Foundation in 2014 with the Excellence Award in Biotechnology; received the Szentagothai Experienced Scientist Award, within the National Excellence Programme, in 2013, won I-st prize for Innovation, Hungarian Academy of Sciences and Baranya County Industrial Board, in 2013 and was honorary senior lecturer and scientist at the University of Birmingham, Birmingham, UK since 2008. In 2009 Prof Pongrácz co-authored and co-edited the award winning book of “Medical Biotechnology” commended by The British Medical Association in the Medical Book Competition Awards.
SAWYER Michael, MD, B.Sc., Phm.
Professor, University of Alberta Medical oncologist and Clinical pharmacologist, Cross Cancer Institute of Alberta Health Services Edmonton, AB, USA
Biography
Dr. Michael Sawyer is a Professor in the Department of Oncology of the University of Alberta, and a medical oncologist and clinical pharmacologist for the Cross Cancer Institute of Alberta Health Services. He obtained his Bachelor of Science in Pharmacy and his MD from the University of Toronto. He completed his fellowship in Medical Oncology fellowship at the University of Western Ontario and completed his training in drug development and Clinical Pharmacology at the University of Chicago Cancer Center. The focus of his research is on causes of inter-patient variability in terms of both toxicity and efficacy to cancer chemotherapy. His research program centers on three fields of study: 1) nucleoside transporters 2) tyrosine kinase inhibitor pharmacology and 3) body composition of cancer patients. He is also the head of the Phase I program at the Cross Cancer Institute.
ZAMEK-GLISZCZYNSKI Maciej, PhD
Senior Fellow and Director, DMPK, GlaxoSmithKline, Collegeville, PA, USA
Biography
Maciej Zamek-Gliszczynski has 15 years of industry (Eli Lilly and GSK) experience in leading DMPK and PK/PD/clinical pharmacology aspects of oncology, endocrine/metabolic, and infectious disease programs at all stages between discovery, clinical development, and post-marketing (6 clinical candidate selections & INDs, 2 NDAs). He is an experienced global manager, having led the Quantitative Drug Disposition group responsible for understanding victim and perpetrator DDIs for the entire GSK portfolio. Dr. Zamek-Gliszczynski’s research is focused on PK/PD and DDI implications of drug and metabolite transport. He is the author of >100 manuscripts and presentations on this subject (>5,000 cites, h-index = 35). He serves on the editorial boards of Pharmaceutical Research and Drug Metabolism and Disposition. Dr. Zamek-Gliszczynski is a member of the International Transport Consortium (ITC) steering committee, was past chair of AAPS PK/PD/Drug Metabolism (PPDM) section, and he served as GSK management representative on IQ Translational ADME Leadership Group (TALG). He has been active in organizing DMPK/clinical pharmacology meetings with ITC, ASCPT and AAPS. Dr. Zamek-Gliszczynski lectures in graduate-level PK/PD courses and serves as external committee advisor (including as adjunct prof at UNC). He enjoys developing scientists and has an established mentorship record at the associate scientist, junior and peer Ph.D., as well as graduate student and post-doc levels.
